Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

NVP-BKM120 1Imatinib Mesylate 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × 3rd Line GIST × Clear all
NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
60 enrolled
Sarcoma

3rd Line GIST

NCT01735968 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
56 enrolled
Sarcoma

3rd Line GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡